CT1812
Cog 0101
Phase 1 small_molecule completed
Quick answer
CT1812 for Cognitive Impairment is a Phase 1 program (small_molecule) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- COGNITION THERAPEUTICS INC
- Indication
- Cognitive Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed